Quality of Life and Cost Study of Rheumatoid Arthritis Therapy With Biological Medicines-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Quality of Life and Cost Study of Rheumatoid Arthritis Therapy With Biological Medicines

Published:2018-07-18 Issue: Volume:9 Page:
ISSN:1663-9812
Container-title:Frontiers in Pharmacology
language:
Short-container-title:Front. Pharmacol.

Author:

Boyadzieva Vladimira V.,Stoilov Nikolay,Stoilov Rumen M.,Tachkov Konstantin,Kamusheva Maria,Mitov Konstantin,Petrova Guenka I.

Publisher

Frontiers Media SA

Subject

Pharmacology (medical),Pharmacology

Reference26 articles.

1. EQ-5D utility, response and drug survival in rheumatoid arthritis patients on biologic monotherapy: a prospective observational study of patients registered in the south Swedish SSATG registry;Jørgensen;PLoS ONE,2017

2. Quality of life in patients with rheumatoid arthritis. Which Drugs Might Make a Difference?;Blumenauer;PharmacoEconomics,2003

3. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis;Aaltonen;PLoS ONE,2012

4. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative;Aletaha;Arthritis Rheum.,2010

5. Economic burden of rheumatoid arthritis: a systematic review;Cooper;Rheumatology,2000

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-Utility Analysis of TNF-α Inhibitors, B Cell Inhibitors, and JAK Inhibitors Versus csDMARDs for Rheumatoid Arthritis Treatment;Applied Health Economics and Health Policy;2024-07-01

2. The Economic Burden of Biological Drugs in Rheumatoid Arthritis Treatment;Value in Health Regional Issues;2024-03

3. Biological ageing: a promising target for prevention and management of rheumatoid arthritis;The Lancet Healthy Longevity;2024-01

4. Health-related quality of life of patients with rheumatoid arthritis on tocilizumab, adalimumab, and etanercept in Saudi Arabia: a single-center cross-sectional study;Frontiers in Pharmacology;2023-12-15

5. How Managed Entry Agreements Influence the Patients’ Affordability to Biological Medicines—Bulgarian Example;Healthcare;2023-08-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3